Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9P021
UPID:
CRIPT_HUMAN
Alternative names:
Cysteine-rich interactor of PDZ three
Alternative UPACC:
Q9P021
Background:
The Cysteine-rich PDZ-binding protein, also known as Cysteine-rich interactor of PDZ three, plays a crucial role in the minor spliceosome's function, facilitating the splicing of U12-type introns in pre-mRNAs. Additionally, it is involved in anchoring DLG4 at excitatory synapses, indicating its importance in synaptic function and structure.
Therapeutic significance:
Linked to the autosomal recessive condition Short stature with microcephaly and distinctive facies, this protein's genetic variants underscore its clinical relevance. Understanding the role of Cysteine-rich PDZ-binding protein could open doors to potential therapeutic strategies for this and possibly other related disorders.